PDCD1 and Merkel cell skin cancer: Pembrolizumab and retifanlimab, monoclonal antibody therapies targeting programmed cell death protein -1 (PD-1), were FDA-approved in 2018 and 2023, respectively, for recurrent, locally advanced and metastatic MCC (77).